BGB-30813 | m-entrepreneurship.com

Product Name :
BGB-30813

Search keywords :
DGKZ

drugId :
null

Target Vo:
Diacylglycerol kinase zeta

Target Vo Short Name :
DGKZ

Moa_Name:
Diacylglycerol kinase zeta inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Beigene Ltd

Active Company_Name :
Beigene Ltd

Active Indication_Name:
Solid tumours

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 1 Clinical

China Highest Status:
Phase 1 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Belantamab In stock
Vopratelimab Technical Information
IGF 1 Antibody: IGF 1 Antibody is an unconjugated, approximately 7.7/21 kDa, rabbit-derived, anti-IGF 1 polyclonal antibody. IGF 1 Antibody can be used for: WB, ELISA, IP, IHC-P, IHC-F, IF expriments in human, mouse, rat, dog, and predicted: pig, cow, rabbit, sheep background without labeling.

Author: Betaine hydrochloride

Related Posts